EA202091611A3 - FILLER-FREE PHARMACEUTICAL COMPOSITION CONTAINING PHENOSANIC ACID - Google Patents

FILLER-FREE PHARMACEUTICAL COMPOSITION CONTAINING PHENOSANIC ACID

Info

Publication number
EA202091611A3
EA202091611A3 EA202091611A EA202091611A EA202091611A3 EA 202091611 A3 EA202091611 A3 EA 202091611A3 EA 202091611 A EA202091611 A EA 202091611A EA 202091611 A EA202091611 A EA 202091611A EA 202091611 A3 EA202091611 A3 EA 202091611A3
Authority
EA
Eurasian Patent Office
Prior art keywords
acid
phenosanic
pharmaceutical composition
hard gelatin
filler
Prior art date
Application number
EA202091611A
Other languages
Russian (ru)
Other versions
EA202091611A2 (en
Inventor
Галина Александровна КИМ
Иван Валерьевич Лапик
Юрий Владимирович ХМЕЛЬЩИКОВ
Original Assignee
Общество С Ограниченной Ответственностью "Консорциум-Пик"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Консорциум-Пик" filed Critical Общество С Ограниченной Ответственностью "Консорциум-Пик"
Publication of EA202091611A2 publication Critical patent/EA202091611A2/en
Publication of EA202091611A3 publication Critical patent/EA202091611A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к фармацевтическим композициям фенозановой кислоты и может быть использовано в качестве лекарственного препарата. Технической задачей, решаемой заявленным изобретением, является создание впервые фармацевтической композиции в виде твердой желатиновой капсулы, содержащей фенозановую кислоту. Техническим результатом, достигаемым при реализации заявленного изобретения, является создание впервые фармацевтической композиции в виде твердой желатиновой капсулы, содержащей фенозановую кислоту, и таким образом расширение арсенала противоэпилептических средств, обладающих ноотропным действием. Технический результат достигается за счет того, что фармацевтическая композиция в виде твердой желатиновой капсулы, содержащей фенозановую кислоту и вспомогательные вещества, содержит в мг на одну капсулу: фенозановую кислоту или ее фармацевтически приемлемую соль - 100-200; разрыхлитель - 40-250; связующее - 2-100; смазывающее - 0,1-4,5.The invention relates to pharmaceutical compositions of phenosanic acid and can be used as a drug. The technical problem solved by the claimed invention is to create for the first time a pharmaceutical composition in the form of a hard gelatin capsule containing phenosanoic acid. The technical result achieved during the implementation of the claimed invention is the creation for the first time of a pharmaceutical composition in the form of a hard gelatin capsule containing phenosanic acid, and thus the expansion of the arsenal of antiepileptic drugs with nootropic action. The technical result is achieved due to the fact that the pharmaceutical composition in the form of a hard gelatin capsule containing phenosanic acid and excipients contains in mg per capsule: phenosanoic acid or its pharmaceutically acceptable salt - 100-200; baking powder - 40-250; binder - 2-100; lubricating - 0.1-4.5.

EA202091611A 2019-07-30 2020-07-29 FILLER-FREE PHARMACEUTICAL COMPOSITION CONTAINING PHENOSANIC ACID EA202091611A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2019124101A RU2736479C1 (en) 2019-07-30 2019-07-30 Excipient-free pharmaceutical composition containing fenosanic acid

Publications (2)

Publication Number Publication Date
EA202091611A2 EA202091611A2 (en) 2021-02-26
EA202091611A3 true EA202091611A3 (en) 2021-04-30

Family

ID=73461155

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091611A EA202091611A3 (en) 2019-07-30 2020-07-29 FILLER-FREE PHARMACEUTICAL COMPOSITION CONTAINING PHENOSANIC ACID

Country Status (2)

Country Link
EA (1) EA202091611A3 (en)
RU (1) RU2736479C1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3928183A1 (en) * 1989-08-25 1991-02-28 Goedecke Ag LACTAM-FREE CYCLIC AMINO ACIDS
ITMI20032399A1 (en) * 2003-12-09 2005-06-10 Zambon Spa PHARMACEUTICAL COMPOSITION CONTAINING GABAPENTIN.
US20110046090A1 (en) * 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
EA017542B1 (en) * 2011-05-24 2013-01-30 Плива Кроэйша Лтд. Stable pharmaceutical composition comprising pregabalin, capsule containing the same, method for producing and use thereof

Also Published As

Publication number Publication date
RU2736479C1 (en) 2020-11-17
EA202091611A2 (en) 2021-02-26

Similar Documents

Publication Publication Date Title
EA202090573A1 (en) COMPOSITIONS OF NIRAPARIBA
DOP2017000293A (en) ORODISPERSABLE DOSAGE UNIT CONTAINING A STETROL COMPONENT
MX2019011491A (en) Niraparib formulations.
RU2017116740A (en) COMBINATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
EA202192322A1 (en) PHARMACEUTICAL COMPOSITIONS
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
PH12021551086A1 (en) Pharmaceutical formulations of cyclosporine analogs
EA201600486A1 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING ANTIKOAGULANT N- (5-CHLORPYRIDIN-2-IL) -2 - ({4- [ETHANIMIDOIL (METHYL) AMINO] BENZOIL} AMINO) -5-METHYLBENZAMIDE
EA202192118A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ACETAMINOPHEN AND IBUPROFEN
EA202091611A2 (en) FILLER-FREE PHARMACEUTICAL COMPOSITION CONTAINING PHENOSANIC ACID
EA201890929A1 (en) LOW DOSES OF DIPYRIDAMOL COMPOSITIONS FOR ORAL ADMINISTRATION AND THEIR USE
EA202091610A2 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING PHENOSANIC ACID
EA202091561A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING PHARMACEUTICALLY ACCEPTABLE ACID-ADDITIVE LENALIDOMIDE SALT
WO2018069805A3 (en) Method for preparation of liquid oral composition of l-thyroxin
EA200500672A1 (en) ALPHUSOSIN-CONTAINING COMPOSITIONS WITH EXTENDED DELIVERY
EA201592297A1 (en) AGOMELATIN COMPOSITIONS CONTAINING AGOMELATIN IN THE FORM OF CRYSTALS
EA201100682A1 (en) STABLE PHARMACEUTICAL COMPOSITION CONTAINING PREGABALIN, CAPSULE, CONTAINING IT, METHOD OF OBTAINING AND APPLICATION
RU2017129068A (en) METHOD OF TREATMENT OR PREVENTION OF ATHEROTROMBOTIC PHENOMENA IN PATIENTS WITH MYOCARDIAL INFARCTION IN ANAMSES
CO2020002625A2 (en) Sulfur colloid pharmaceutical compositions and processes thereof
AR016017A1 (en) PHARMACEUTICAL FORMULATIONS AND PROCESS FOR PREPARATION
RU2017129085A (en) New N-carbamoylmethyl-4-phenyl-2-pyrrolidone formulation
EA201991381A1 (en) Composition for the treatment of osteoarthritis
RU2013126798A (en) COMBINED THERAPY BY DEXAMETASONE
RU2018144248A (en) Dosing regimens for vortioxetine for rapid onset of antidepressant effect
EA201890101A1 (en) NEW SCHEME TREATMENT TYACUMICINE CONNECTION